PMID- 28646700
OWN - NLM
STAT- MEDLINE
DCOM- 20180201
LR  - 20181202
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 130
DP  - 2017 Aug
TI  - Increased serum miR-7 is a promising biomarker for type 2 diabetes mellitus and 
      its microvascular complications.
PG  - 171-179
LID - S0168-8227(16)31836-8 [pii]
LID - 10.1016/j.diabres.2017.06.005 [doi]
AB  - AIMS: To investigate the alteration pattern and physiologic state of 
      islet-specific miR-7 in the serum of patients with type 2 diabetes mellitus 
      (T2DM) and T2DM-associated microvascular complications (T2DMC) and to evaluate 
      its clinical significance. METHODS: The levels of serum miR-7 were firstly 
      examined and compared in 76 T2DM patients, 76 T2DMC patients and 74 age-gender 
      matched controls using RT-qPCR. Subsequently, the physiologic state of serum 
      miR-7 was characterized by determining its concentrations in isolated exosomes 
      and corresponding exosome-free samples from the same three cohorts' samples. 
      Moreover, statistical analyzes were performed to evaluate the associations of 
      serum miR-7 with T2DM and T2DMC. RESULTS: Serum miR-7 was significantly elevated 
      in the T2DM patients [(401.0+/-34.37) fmol/L, P<0.001] and in the T2DMC patients 
      [(501.4+/-81.69) fmol/L, P<0.001] when compared with the controls [(175.7+/-16.59) 
      fmol/L]. Circulating miR-7 was mainly existed as exosome-free form rather than in 
      membrane-bound exosomes. The concentrations of exosome-free miR-7 were markedly 
      higher in the T2DM group [(107.2+/-9.63) fmol/L, P<0.001] and in the T2DMC group 
      [(122.1+/-10.80) fmol/L, P<0.001] compared to the control group [(54.18+/-2.37) 
      fmol/L]. Logistic regression and ROC curve analyses revealed the serum miR-7 was 
      significantly associated with T2DM and microvascular complications (P<0.05). 
      CONCLUSION: Increased serum miR-7 might have the potential as a promising marker 
      for T2DM and its microvascular complications.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Wan, Shujun
AU  - Wan S
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China; State Key Laboratory of Pharmaceutical 
      Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University 
      School of Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology 
      and Biotechnology, Nanjing University, Nanjing 210023, China.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Cardiology, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Wu, Jia
AU  - Wu J
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Song, Jiaxi
AU  - Song J
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Zhang, Chen-Yu
AU  - Zhang CY
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Nanjing Advanced Institute 
      for Life Sciences, Nanjing University School of Life Sciences, Jiangsu 
      Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing 
      University, Nanjing 210023, China.
FAU - Zhang, Chunni
AU  - Zhang C
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China; State Key Laboratory of Pharmaceutical 
      Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University 
      School of Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology 
      and Biotechnology, Nanjing University, Nanjing 210023, China.
FAU - Wang, Cheng
AU  - Wang C
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China; State Key Laboratory of Pharmaceutical 
      Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University 
      School of Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology 
      and Biotechnology, Nanjing University, Nanjing 210023, China. Electronic address: 
      wangcheng919@smail.nju.edu.cn.
FAU - Wang, Jun-Jun
AU  - Wang JJ
AD  - Department of Clinical Laboratory, Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China; State Key Laboratory of Pharmaceutical 
      Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University 
      School of Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology 
      and Biotechnology, Nanjing University, Nanjing 210023, China. Electronic address: 
      wangjunjun9202@163.com.
LA  - eng
PT  - Journal Article
DEP - 20170611
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Biomarkers)
RN  - 0 (MIRN7 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/genetics
MH  - Diabetic Angiopathies/*blood/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - MicroRNAs/*blood/genetics
MH  - Middle Aged
OTO - NOTNLM
OT  - Biomarkers
OT  - Microvascular complications
OT  - Serum microRNA
OT  - Type 2 diabetes
OT  - miR-7
EDAT- 2017/06/25 06:00
MHDA- 2018/02/02 06:00
CRDT- 2017/06/25 06:00
PHST- 2016/12/24 00:00 [received]
PHST- 2017/04/15 00:00 [revised]
PHST- 2017/06/06 00:00 [accepted]
PHST- 2017/06/25 06:00 [pubmed]
PHST- 2018/02/02 06:00 [medline]
PHST- 2017/06/25 06:00 [entrez]
AID - S0168-8227(16)31836-8 [pii]
AID - 10.1016/j.diabres.2017.06.005 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2017 Aug;130:171-179. doi: 
      10.1016/j.diabres.2017.06.005. Epub 2017 Jun 11.